<DOC>
	<DOCNO>NCT01310244</DOCNO>
	<brief_summary>To define Phase 1/2 Maximum Tolerated Dose Study Belinostat ( PXD-101 ) Combination Paclitaxel plus Carboplatin Chemotherapy-Naive Patients Stage IV Non-Small-Cell Lung Cancer ( NSCLC ) .</brief_summary>
	<brief_title>Maximum Tolerated Dose Study Belinostat ( PXD-101 ) Combination With Paclitaxel Plus Carboplatin Chemotherapy-Naive Patients With Stage IV Non-Small-Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>This Phase 1/2 , multi-center , open label single arm study . Patients meet inclusion exclusion criterion receive 6 cycle combination therapy belinostat plus carboplatin ( AUC 6 ) paclitaxel 200 mg/m2 . During phase I Maximum Tolerated Dose ( MTD ) belinostat combination carboplatin paclitaxel determine patient Stage IV non-small cell lung cancer receive prior systemic chemotherapy . The dose escalation study conduct use traditional escalation rule 3+3 design , first cycle therapy . Belinostat assess start dose level 1000 mg/m2 multiple dose level may evaluate . Doses belinostat , carboplatin paclitaxel remain constant throughout study , unless dose modification require toxicity . Treatment give day 1-5 every 21-day cycle . Routine safety evaluation conduct day , 1 , 8 , 15 every cycle . Tumor measurement do every 2 cycle treatment . Additional 20 patient treat MTD define dose phase II expansion portion study . All patient receive 6 cycle combination therapy follow occurrence unacceptable toxicity , disease progression , withdrawal consent death .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>A histologically cytologically confirm diagnosis Stage IV ( M1a M1b ) NSCLC . Patients mixed nonsmall cell histology eligible No prior chemotherapy treatment advance NSCLC Prior adjuvant therapy early stage lung cancer allow complete ≥ 12 month prior enrollment Age &gt; = 18 year Adequate organ function Any treatment investigational agent must complete ≥ 4 week prior enrollment Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Negative pregnancy test woman childbearing potential . Patients brain metastasis allow : Directed local therapy complete 2 week prior enrollment ; There evidence disease progression ; Steroids require Patients mixed tumor small cell feature Known infection HIV , hepatitis B hepatitis C Baseline prolongation QT/QTcF interval require concomitant medication may cause Torsade de Pointes Preexisting ≥Grade 2 neuropathy Valproic acid treatment within 2 week study enrollment Systemic steroid , indication , stabilize &gt; 10 mg/day prednisone Known allergy hypersensitivity component belinostat , paclitaxel carboplatin Coexisting active infection uncontrolled medical condition likely interfere trial procedure Active concurrent malignancy ( except basal cell carcinoma cervical intraepithelial neoplasia , potentially cured malignancy remission five year prior adjuvant therapy early stage lung cancer complete ≥ 12 month ago ) Pregnant breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Phase 1/2</keyword>
	<keyword>MTD</keyword>
	<keyword>stage IV</keyword>
	<keyword>NSCLC</keyword>
	<keyword>chemo-naive</keyword>
	<keyword>Mixed-cell dose escalation</keyword>
	<keyword>lung cancer</keyword>
	<keyword>non-small-cell</keyword>
	<keyword>phase I</keyword>
	<keyword>Belinostat</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>PXD-101</keyword>
</DOC>